Vogt-Koyanagi-Harada–like Syndrome Complicating Pembrolizumab Treatment for Metastatic Melanoma. Issue 2 (February 2017)

• Record Type: Journal Article
• Authors: Bricout, Marion; Petre, Adeline; Amini-Adle, Mona; Bezza, Widad; Seve, Pascal; Kodjikian, Laurent; Dalle, Stéphane; Thomas, Luc
• Is Part Of: Journal of immunotherapy. Volume 40:Issue 2(2017:Feb./Mar.)
• Publication Date: 2017-02
• Subjects: Vogt-Koyanagi-Harada syndrome -- uveitis -- melanoma -- toxicity -- anti-PD-1 -- immunotherapy; Immunotherapy -- Periodicals; Immunotherapy -- Periodicals; Neoplasms -- therapy -- Periodicals; Electronic journals; Electronic journals; 615.37
• DOI: 10.1097/CJI.0000000000000154
• Languages: English
• ISSNs: 1524-9557

Abstract

Abstract : Vogt-Koyanagi-Harada (VKH) syndrome is a rare condition implicating systemic immune reaction against melanocytes. The pathophysiology is unclear. A genetic predisposition has been suggested as HLA-DR4/DRB1*04 is more common among VKH patients. Drug induced VKH syndrome has been reported in advanced melanoma patients receiving immunotherapy, including ipilimumab and adoptive cell transfer of Tumor-Infiltrating Lymphocyte associated with IL-2. To date, no case of anti PD-1 -induced VKH syndrome has been described. We report here the case of a HLA-DR4/DRB1*04 patient successfully treated with anti PD-1 for advanced melanoma who developed a systemic immune reaction against melanocytes for whom we discuss a VKH-like syndrome diagnosis in a potentially genetically predisposed patient.